An Investigation Into the Effects of a Wild Blueberry Powder and a Wild Blueberry Extract on Cognition in Older Adults
NCT ID: NCT02446314
Last Updated: 2019-08-08
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
122 participants
INTERVENTIONAL
2015-05-31
2017-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Blueberry Supplementation on Cognitive Functioning in Older Adults
NCT07170943
Effects of Blueberry Juice Consumption on Cognitive Function in Healthy Older People
NCT02985580
Investigating the Effects of Daily Consumption of Blueberry (Poly)Phenols on Vascular Function and Cognitive Performance
NCT04084457
Investigating the Acute Effects of Blueberry (Poly)Phenols on Vascular Function and Cognition in Healthy Individuals.
NCT03592966
Effects of Blueberry on Cognition and Mobility in Older Adults
NCT01888848
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Procedure: The study comprises of a telephone screen and then six visits, including a familiarization visit (week T-1), three test visits (week 0, 12 and 24), and two control visits (week 6 and 18). Participants may stop the study treatment without stating any reason at any time during the study. In addition, a participant will be withdrawn from the study if: a subject requests discontinuation, he/she exhibits a serious adverse event to any component of the test product, the participant significantly violates the inclusion or exclusion criteria, an intercurrent illness emerges and/or the investigator's opinion is that withdrawal is appropriate and in the best interest of the participant. If a participant withdraws from the study, he/she will be encouraged to make a final visit as soon as possible, irrespective of the reason for withdrawal, to complete a final battery of cognitive tasks.
1. Screening: once a participant has indicated that they wish to join the trial they will be contacted by telephone for a brief screening session. The research associate (RA) will give a brief overview of the study and will ascertain that each interested volunteer is willing to participate for the entire duration of the study and to check that they fulfill our inclusion/exclusion criteria. Once confirmation of suitability for the study is confirmed, the RA will schedule their familiarization visit.
2. Familiarization Visit: Volunteers will be asked to attend the Nutritional Psychology Unit at the University of Reading where they will receive a detailed explanation on the study by the participating research associate and will be asked to sign the informed consent form before any study procedure starts. A log will be kept identifying all participants having signed the informed consent form (ICF) and the participant will be allocated a participant number. Once consent has been given, the inclusion/exclusion criteria will be checked once again and vital signs (blood pressure and heart rate) and anthropometric measurements (height, weight, BMI) will be taken. The participants will then be asked to complete a number of questionnaires and cognitive tasks comprising: (i) Yale Physical Activity Questionnaire; (ii) Frequency of Forgetting Questionnaire to give a baseline assessment of their memory performance; and (iii) Computerized Global Cognitive Health Assessments (NART, CERAD, MMSE, letter and category fluency; unless as a member of the Older Adult Panel these data have been collected from them in the preceding 3 months). Finally, participants will be given training on the cognitive test battery (tasks outlined below) that will be used during the study to reduce the chances of 'practice' adversely effecting performance on subsequent test days. Before leaving the laboratory, participants will be asked to keep a 72 hour food diary (consisting of 2 week days \& 1 weekend day) so that background flavonoid intakes can be measured prior to the start of the intervention.
3. Test Visits (Weeks 0, 12 and 24): All of these sessions will be held in the morning (typically 8am-10am arrival time to suit participants individual needs). Participants will attend the laboratory in a fasted state and on arrival at the laboratory we will check participants still fulfill our inclusion/exclusion criteria, their general well-being, notification of any adverse events, any issues with compliance, and to check whether there have been changes to any concomitant medication. Blood pressure and heart rate will also be measured, and the food diary will be collected (week 0 and 24 only). They will then receive a standard low-flavonoid breakfast and will complete the battery of cognitive tasks (see below). Subjects will then be given their intervention (sufficient quantity until their next test session, in blister packs, weeks 0 and 12 only), and will then be requested to consume 2 capsules each day. At week 24 only, the Yale Physical Activity and Frequency of Forgetting questionnaires will also be administered, and weight will be measured.
4. Control Visits (weeks 6 \& 18): These sessions can take place at any time of day to suit the participant. Participants will attend the laboratory at the University of Reading to collect the next 6 week supply of their intervention. During these visits we will check that participants still fulfill our inclusion/exclusion criteria, informally check their well-being, inquire whether there have been any adverse events, and confirm that there have not been any changes to their concomitant medication. At week 18 only participants will be given another copy of the 72 hour food diary (consisting of 2 week days \& 1 weekend day and asked to complete this before they return for their test visit in week 24.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Formulation containing inert artificially colored maltodextrin, once daily, in a 2-hard capsule regimen
Placebo
Formulation containing inert artificially colored maltodextrin, once daily, in a 2-hard capsule regimen
Wild Blueberry Powder - 450mg
Formulation containing 225 mg wild blueberry powder + 22.5 mg L-Cysteine + 2.5 mg L-Glutathione + 250 mg placebo powder, once daily, in a 2-hard capsule regimen
Wild Blueberry Powder - 450mg
Formulation containing 225 mg wild blueberry powder + 22.5 mg L-Cysteine @ 2.5 mg L-Glutathione 250 mg placebo powder, once daily, in a 2-hard capsule regimen
Wild Blueberry Powder - 900 mg
Formulation containing containing 450 mg wild blueberry powder + 45 mg L-Cysteine + 5 mg L-Glutathione once daily, in a 2-hard capsule regimen
Wild Blueberry Powder - 900 mg
Formulation containing 450 mg wild blueberry powder = 45 mg L-Cysteine + 5 mg L-Glutathione once daily, in a 2-hard capsule regimen
Wild Blueberry extract 100mg
Formulation containing containing 100 mg wild blueberry powder + 10 mg L-Cysteine + 1 mg L-Glutathione + 389 mg of placebo, once daily, in a 2-hard capsule regimen
Wild Blueberry extract 100mg
Formulation containing 100 mg wild blueberry powder + 10 mg L-Cysteine + 1 mg L-Glutathione + 389 mg of placebo, once daily, in a 2-hard capsule regimen
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Formulation containing inert artificially colored maltodextrin, once daily, in a 2-hard capsule regimen
Wild Blueberry Powder - 450mg
Formulation containing 225 mg wild blueberry powder + 22.5 mg L-Cysteine @ 2.5 mg L-Glutathione 250 mg placebo powder, once daily, in a 2-hard capsule regimen
Wild Blueberry Powder - 900 mg
Formulation containing 450 mg wild blueberry powder = 45 mg L-Cysteine + 5 mg L-Glutathione once daily, in a 2-hard capsule regimen
Wild Blueberry extract 100mg
Formulation containing 100 mg wild blueberry powder + 10 mg L-Cysteine + 1 mg L-Glutathione + 389 mg of placebo, once daily, in a 2-hard capsule regimen
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Free-living
* Subjects with subjective memory complaints
* MMSE: 24-30
* Subjects are willing to maintain their normal eating habits and exercise habits to avoid changes in body weight over the duration of the study
* Being willing to complete the food diaries and questionnaires
* Able to give signed written informed consent
* Signed informed consent form
Exclusion Criteria
* History of metabolic disorder, diabetes, substance abuse
* Subjects diagnosed with psychiatric or neurological conditions
* Subjects using medications that might affect the outcome measures (such as antidepressant and sleeping medication), or planned changes
65 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Naurex, Inc, an affiliate of Allergan plc
INDUSTRY
University of Reading
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof Claire Williams
Associate Professor in Behavioural Neuroscience
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Claire M Williams, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Reaiding
Emilie Fromentin, PhD
Role: STUDY_DIRECTOR
NATURIEX-DBS,, LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Reading
Reading, Berkshire, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
How, P.S., Ellis, J.A., Neshatdoust, S., Spencer, J.P.E. (2008). The impact of plant-derived flavonoids on mood, memory and motor skills in healthy older UK adults. Proceedings of the Nutrition Society, 67, E316.
Krikorian R, Shidler MD, Nash TA, Kalt W, Vinqvist-Tymchuk MR, Shukitt-Hale B, Joseph JA. Blueberry supplementation improves memory in older adults. J Agric Food Chem. 2010 Apr 14;58(7):3996-4000. doi: 10.1021/jf9029332.
Macready AL, Kennedy OB, Ellis JA, Williams CM, Spencer JP, Butler LT. Flavonoids and cognitive function: a review of human randomized controlled trial studies and recommendations for future studies. Genes Nutr. 2009 Dec;4(4):227-42. doi: 10.1007/s12263-009-0135-4. Epub 2009 Aug 13.
Rendeiro C, Vauzour D, Kean RJ, Butler LT, Rattray M, Spencer JP, Williams CM. Blueberry supplementation induces spatial memory improvements and region-specific regulation of hippocampal BDNF mRNA expression in young rats. Psychopharmacology (Berl). 2012 Oct;223(3):319-30. doi: 10.1007/s00213-012-2719-8. Epub 2012 May 9.
Rendeiro C, Vauzour D, Rattray M, Waffo-Teguo P, Merillon JM, Butler LT, Williams CM, Spencer JP. Dietary levels of pure flavonoids improve spatial memory performance and increase hippocampal brain-derived neurotrophic factor. PLoS One. 2013 May 28;8(5):e63535. doi: 10.1371/journal.pone.0063535. Print 2013.
Whyte AR, Cheng N, Fromentin E, Williams CM. A Randomized, Double-Blinded, Placebo-Controlled Study to Compare the Safety and Efficacy of Low Dose Enhanced Wild Blueberry Powder and Wild Blueberry Extract (ThinkBlue) in Maintenance of Episodic and Working Memory in Older Adults. Nutrients. 2018 May 23;10(6):660. doi: 10.3390/nu10060660.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RDG-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.